306 related articles for article (PubMed ID: 23714558)
1. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
Long GV; Margolin KA
Am Soc Clin Oncol Educ Book; 2013; ():393-8. PubMed ID: 23714558
[TBL] [Abstract][Full Text] [Related]
2. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
5. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
[TBL] [Abstract][Full Text] [Related]
6. Melanoma brain metastasis: overview of current management and emerging targeted therapies.
Fonkem E; Uhlmann EJ; Floyd SR; Mahadevan A; Kasper E; Eton O; Wong ET
Expert Rev Neurother; 2012 Oct; 12(10):1207-15. PubMed ID: 23082737
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastases harboring BRAF
Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases.
Ramakrishna N; Margolin KA
Am Soc Clin Oncol Educ Book; 2013; ():399-403. PubMed ID: 23714560
[TBL] [Abstract][Full Text] [Related]
13. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
14. The role of systemic therapies in the management of melanoma brain metastases.
Lyle M; Long GV
Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
17. [Melanoma brain metastases : Treatment options].
Rauschenberg R; Tabatabai G; Troost EG; Garzarolli M; Beissert S; Meier F
Hautarzt; 2016 Jul; 67(7):536-43. PubMed ID: 27206449
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
19. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
20. How I treat brain metastases of melanoma.
Eroglu Z; Topcu TO; Yu HM; Margolin KA
ESMO Open; 2022 Dec; 7(6):100598. PubMed ID: 36274439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]